Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 eu ...

SMA Altenso is to provide the full EPC and O&M services for the battery park, which is scheduled to go online in the second half of 2025. MEAG Munich Ergo Assetmanagement GmbH has agreed with SMA ...

SMA is also pushing ahead with capacity expansion in Germany, where it plans to reach 40 GW. It said it wants to produce solutions for large PV projects and storage systems from 2025 at its ...

German teachers in the US shape the image of Germany in the US and facilitate the transatlantic dialogue between the US and Germany. Unfortunately, the number of German programs at all levels is ...

On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two ...

Swiss pharma giant Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study ...